MedTrace Logo

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

NCT00698490 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2008-06-17

No results posted yet for this study

Summary

The purpose of the study is to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control.

Conditions

  • Prophylaxis Herpes Simplex

Interventions

BIOLOGICAL

Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141

Intramuscular injection, 3 doses, 2 different formulations

BIOLOGICAL

Herpes simplex virus containing gD-Alum

Intramuscular injection, 3 doses

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1995-08-31
Primary Completion
1997-01-31
Completion
1997-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698490 on ClinicalTrials.gov